Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Inhaled xenon shifts microglia from a pro-inflammatory to a phagocytic state. Interferon-γ released by peripheral T cells flips the switch. In mice, xenon curbed plaques and dystrophic neurites. A ...

Today the U.S. Food and Drug Administration’s advisory committee gave the nod to donanemab, clearing the way for its marketing approval. All 11 members voted that the antibody was effective for people ...

For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and ...

Series - AD/PD™ 2024: Advances in Science & Therapy: Part 1 of 9: Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024 Part 2 of 9: TauRx Parses Subgroups to Make the Case for ...

Recent proteomic studies have offered glimpses into the biology of early Alzheimer’s disease. Two new preprints take this approach further, describing high-throughput surveys that turned up numerous ...

Studies aim to validate Alzheimer's disease blood tests against gold standard biomarkers in primary care. Scientists ask how best to incorporate AD blood tests into existing healthcare systems. Some ...

In mice, APOE3-Christchurch reduced amyloidosis, tauopathy, and tau spreading. Two copies of APOE4-Christchurch staved off tangles, gliosis, and neurodegeneration. Just one copy reduced gliosis and ...